(édition révisée de 2020, telle que modifiée jusqu’au 1er novembre 2022)
RetourVersion la plus récente dans WIPO LexDétailsDétailsAnnée de version2022DatesModifié jusqu’à:1 novembre 2022Lancé:3 mai 1993Type de texte
Autres textes
Sujet
Information non divulguée (Secrets commerciaux)
Notes This consolidated version of the Medicines Act 1975 incorporates amendments up to the Statutes (Miscellaneous Amendments) Act 2022 (Act No. 31 of 2022), which entered into force on multiple dates: November 1, 2022; November 1, 2023; June 1, 2024; October 15, 2024; and September 1, 2025. The said amending Act No. 31 of 2022 introduced amendments (in force from November 1, 2022) to this consolidated version as follows: - Sections 12A, 19A, 19B, 19C, 19D are deleted. - Subsections 16(3), 16(6), 20(4) are deleted. - Section 20(3) is amended to remove reference to section 12A(2). - Section 20(6) is amended to adjust cross-references. - Section 76(1) is deleted. Section 62 entitled "Restrictions on disclosure of information" under Part 6 of this consolidated version provides that any person who gains access to a manufacturing process, trade secret, or other information under the authority of the Act (for example, during inspections under section 56) must keep that information confidential. If they disclose such information to anyone without authorization and not in the performance of their official duties, they commit an offence. The penalty for unauthorized disclosure is a fine of up to $5,000, imprisonment for up to 2 years, or both.